A RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIDEGLUSIB VERSUS PLACEBO FOR THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH CONGENITAL MYOTONIC DYSTROPHY

Registry ID

AMO-02-MD-2-003

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

AMO PHARMA LTD

Start date

2022-05-03

Completion date

2023-04-04

Last update

2018-01-26

Conditions

• CONGENITAL MYOTONIC DYSTROPHY

Related clinical trials

• A PHASE 1/PHASE 2 OPEN-LABEL SINGLE ARM STUDY WITH DOSE ESCALATION (PART A), AND DOSE EXPANSION (PART B) PARTS TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF SAR446268, AN ADENO-ASSOCIATED VIRAL VECTOR-MEDIATED GENE THERAPY IN PARTICIPANTS 10 TO 50 YEARS OLD WITH NON-CONGENITAL MYOTONIC DYSTROPHY TYPE 1
• A 52-WEEK, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF TIDEGLUSIB FOR THE TREATMENT OF CONGENITAL DM1 (REACH CDM X)

View on source registry